Apellis Pharmaceuticals Inc (APLS)vsInsmed Inc (INSM)
APLS
Apellis Pharmaceuticals Inc
$17.72
+2.84%
HEALTHCARE · Cap: $2.27B
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Apellis Pharmaceuticals Inc generates 66% more annual revenue ($1.00B vs $606.42M). APLS leads profitability with a 2.2% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
APLS
Avoid30
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1728.7%
Fair Value
$1.22
Current Price
$17.72
$16.50 premium
Intrinsic value data unavailable for INSM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
2.2% margin — thin
Elevated debt levels
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : APLS
APLS has a balanced fundamental profile.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : APLS
The primary concerns for APLS are EPS Growth, Return on Equity, Profit Margin. A P/E of 98.4x leaves little room for execution misses. Thin 2.2% margins leave little buffer for downturns.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
APLS profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
APLS generates stronger free cash flow (-14M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 30/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Apellis Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through inhibition of the complement system for autoimmune and inflammatory diseases. The company is headquartered in Waltham, Massachusetts.
Visit Website →Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?